News | November 16, 2025
ALBIS unveils next-gen healthcare materials at COMPAMED 2025
ALBIS will present a selection of advanced materials from its broad healthcare portfolio
ALBIS will present a selection of advanced materials from its broad healthcare portfolio
Acquisition brings highly differentiated clinical-stage obesity candidates with potential to reshape the treatment landscape
Sepsis is a life-threatening reaction to infection that overwhelms the body’s defenses
Novartis is the only pharmaceutical company with a dedicated commercial RLT portfolio
LANXESS will highlight its commitment to combatting antimicrobial resistance by presenting science-based disinfection solutions
Hyaluronic acid is among the world's most valuable biopolymers, with applications spanning from dermal fillers and wound healing to drug delivery and tissue engineering
The new company aims to transform cutting-edge, highly scalable technologies into innovative drug discovery platforms
New site expands manufacturing footprint to meet future demand; ensures continued on-time delivery rate of >99.9% to patients across western US, Alaska and Hawaii
Tinostamustine is an investigational drug with a potential first-in-class mechanism combining bifunctional alkylating activity and pan histone deacetylase (HDAC) inhibition
The expanded mbDNA portfolio delivers enhanced stability, reduced immunogenicity, and broad compatibility with gene insertion and expression technologies
Subscribe To Our Newsletter & Stay Updated
